Evidence map›Paper›PMID 29112689›Full record

ArticlePLoS medicine2017

HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis.

Tonia Poteat, Benjamin Ackerman, Daouda Diouf, Nuha Ceesay, Tampose Mothopeng, Ky-Zerbo Odette, Seni Kouanda, Henri Gautier Ouedraogo, Anato Simplice, Abo Kouame and 5 more

Abstract read
In one paragraph

Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Tonia PoteatEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID http://orcid.org/0000-0001-6541-3787
Benjamin AckermanBiostatistics Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Daouda DioufEnda Sante, Dakar, Senegal.
Nuha CeesayJoint United Nations Programme on HIV and AIDS Country Office, Mbabane, Swaziland.
Tampose MothopengPeople's Matrix Association, Maseru, Lesotho.
Ky-Zerbo OdetteProgramme d'Appui au Monde Associatif et Communautaire, Ouagadougou, Burkina Faso.
Seni KouandaInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Henri Gautier OuedraogoInstitut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.
Anato SimpliceONG Arc-en-Ciel, Lomé, Togo.
Abo KouameMinistère de la Sante et de l'Hygiène Publique, Abidjan, Côte d'Ivoire.
Zandile MnisiHealth Research Department, Strategic Information Division, Ministry of Health, Mbabane, Swaziland.ORCID http://orcid.org/0000-0001-6479-3773
Gift TrapenceCentre for the Development of People, Lilongwe, Malawi.
L Leigh Ann van der MerweSocial, Health, and Empowerment Feminist Collective of Transgender Women of Africa, East London, South Africa.
Vicente JumbeMalawi College of Medicine, Blantyre, Malawi.
Stefan BaralEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Minority Populations Prevention Researcher TrainingR25HD045810 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEILANDS, TORSTEN BRIAN · 2003 to 2018
$4.3M
Validation of Stigma Metrics for Marginalized Men R01MH110358 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BARAL, STEFAN DAVID · 2017 to 2021
$3.6M
NIAID NIH HHS P30 AI094189NICHD NIH HHS R25 HD045810NIMH NIH HHS R01 MH110358
6 · The paper itself

Abstract

introductionSub-Saharan Africa bears more than two-thirds of the worldwide burden of HIV; however, data among transgender women from the region are sparse. Transgender women across the world face significant vulnerability to HIV. This analysis aimed to assess HIV prevalence as well as psychosocial and behavioral drivers of HIV infection among transgender women compared with cisgender (non-transgender) men who have sex with men (cis-MSM) in 8 sub-Saharan African countries. METHODS AND

findingsRespondent-driven sampling targeted cis-MSM for enrollment. Data collection took place at 14 sites across 8 countries: Burkina Faso (January-August 2013), Côte d'Ivoire (March 2015-February 2016), The Gambia (July-December 2011), Lesotho (February-September 2014), Malawi (July 2011-March 2012), Senegal (February-November 2015), Swaziland (August-December 2011), and Togo (January-June 2013). Surveys gathered information on sexual orientation, gender identity, stigma, mental health, sexual behavior, and HIV testing. Rapid tests for HIV were conducted. Data were merged, and mixed effects logistic regression models were used to estimate relationships between gender identity and HIV infection. Among 4,586 participants assigned male sex at birth, 937 (20%) identified as transgender or female, and 3,649 were cis-MSM. The mean age of study participants was approximately 24 years, with no difference between transgender participants and cis-MSM. Compared to cis-MSM participants, transgender women were more likely to experience family exclusion (odds ratio [OR] 1.75, 95% CI 1.42-2.16, p < 0.001), rape (OR 1.95, 95% CI 1.63-2.36, p < 0.001), and depressive symptoms (OR 1.30, 95% CI 1.12-1.52, p < 0.001). Transgender women were more likely to report condomless receptive anal sex in the prior 12 months (OR 2.44, 95% CI 2.05-2.90, p < 0.001) and to be currently living with HIV (OR 1.81, 95% CI 1.49-2.19, p < 0.001). Overall HIV prevalence was 25% (235/926) in transgender women and 14% (505/3,594) in cis-MSM. When adjusted for age, condomless receptive anal sex, depression, interpersonal stigma, law enforcement stigma, and violence, and the interaction of gender with condomless receptive anal sex, the odds of HIV infection for transgender women were 2.2 times greater than the odds for cis-MSM (95% CI 1.65-2.87, p < 0.001). Limitations of the study included sampling strategies tailored for cis-MSM and merging of datasets with non-identical survey instruments.

conclusionsIn this study in sub-Saharan Africa, we found that HIV burden and stigma differed between transgender women and cis-MSM, indicating a need to address gender diversity within HIV research and programs.

Indexed as

Sexual BehaviorAdolescentAdultAfrica South of the SaharaCross-Sectional StudiesFemaleHealth SurveysHIV InfectionsHumansMaleMiddle AgedPrevalenceRisk FactorsSocial StigmaTransgender Persons

Identifiers

PMID29112689
PMCPMC5675306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.